{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-100801","form_type":"8-K","ticker":"IMNM","cik":"0001472012","company_name":"Immunome Inc.","filed_at":"2021-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.194883+00:00","generated_at":"2026-06-29T21:31:43.521222+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Immunome CSO Michael Morin resigns to part-time Chief Scientist; salary cut to $60,000","bullets":["Michael Morin resigned as CSO and EVP effective Aug 1, 2021; now part-time Chief Scientist (~5 days/month).","Annual base salary reduced to $60,000; eligible for prorated 2021 bonus (target 40% of prior salary, 7 months).","Equity vesting continues unchanged under existing grant agreements.","Morin will report to Chief Development Officer and work primarily from home office."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-100801","json":"https://secwatch.observer/filing/0001104659-21-100801.json","markdown":"https://secwatch.observer/filing/0001104659-21-100801.md","text":"https://secwatch.observer/filing/0001104659-21-100801.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472012/000110465921100801/0001104659-21-100801-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472012/000110465921100801/tm2124229d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T21:31:43.521222+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ad0b1e1ebe","claim":"Michael J. Morin was appointed as Chief Scientist at Immunome Inc..","evidence_excerpt":"Dr. Morin resigned from his positions as Chief Scientific Officer and Executive Vice President of the Company. Pursuant to the Employment Agreement, Dr. Morin will be employed by the Company on a part-time basis as its Chief Scientist.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472012/000110465921100801/0001104659-21-100801-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Scientist"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}